Intravesical gemcitabine and docetaxel vs. re‐induction Bacillus Calmette Guerin as first‐line salvage therapy for non‐muscle invasive bladder cancer
Our initial experience with intravesical Gem/Doce suggests that it is better tolerated, with fewer adverse events and comparable recurrence rates at three months, compared to re-induction BCG in patients with BCG-failure NMIBC.
Authors
- Scott Donnellan
- Tran Ngoc An Huynh (ORCID: https://orcid.org/0000-0001-7027-2819)
- Jeanine B. Downie
- Weranja Ranasinghe (ORCID: https://orcid.org/0000-0002-4006-0388)
- O. Fazli
- Kylie Yen‐Yi Lim
- Gavin Wei (ORCID: https://orcid.org/0000-0001-5168-6346)
- David Pook (ORCID: https://orcid.org/0000-0002-1744-3022)
- Joseph Kuriakose
- Sarah Ransley
Institutions
- Monash Health (AU)
- Monash University (AU)
Publication Details
- Journal
- BJUI Compass
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/bco2.70012
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01